Keynote 224 Results In . Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: Results of a 2 y follow.
In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on. Patients were required to have.
Source: www.thelancet.com
Pembrolizumab in patients with advanced hepatocellular carcinoma , Pembrolizumab received accelerated approval in november 2018 for patients with hcc who had previously been treated with sorafenib, based on orr and.
Source: www.ejcancer.com
Updated efficacy and safety of KEYNOTE224 a phase II study of , In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on.
Source: oncologiabrasil.com.br
KEYNOTE224 Avaliação da monoterapia com pembrolizumabe para carcinoma , Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma.
Source: www.ejcancer.com
Updated efficacy and safety of KEYNOTE224 a phase II study of , In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on.
Source: www.pd1.cn
Keynote224研究完整数据公布，帕博利珠单抗如何在“OK”之争中更胜一筹？咚咚肿瘤科 , In patients (pts) with previously treated ahcc, pembro demonstrated comparable efficacy and safety vs placebo (pbo) in the phase 3.
Source: www.thelancet.com
Pembrolizumab in patients with advanced hepatocellular carcinoma , In patients (pts) with previously treated ahcc, pembro demonstrated comparable efficacy and safety vs placebo (pbo) in the phase 3.
Source: medi-paper.com
ASCO 2018 HCC The ASCO18 hepatocellular cancer track summarised , In patients (pts) with previously treated ahcc, pembro demonstrated comparable efficacy and safety vs placebo (pbo) in the phase 3.
Source: europepmc.org
Pembrolizumab Monotherapy for Previously Untreated Advanced , We aimed to assess the efficacy and safety of.
Source: k.sina.cn
K药二线治疗晚期肝癌研究KEYNOTE224 , We aimed to assess the efficacy and safety of.
Source: www.sohu.com
文献速递（第341期）—先前接受索拉非尼治疗的晚期肝细胞癌患者中的Pembrolizumab的应用（KEYNOTE224）_研究 , Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: